Services - 111630-2021

05/03/2021    S45

Belgium-Brussels: Research and experimental development services

2021/S 045-111630

Prior information notice

This notice is for prior information only


Legal Basis:
Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
Official name: Sciensano
Postal address: J.Wytsmansstraat
Town: Brussels
NUTS code: BE Belgique / België
Postal code: 1050
Country: Belgium
Contact person: Marc van den Bulcke
Telephone: +32 474940931
Internet address(es):
Main address:
Address of the buyer profile:
I.1)Name and addresses
Official name: Alleanza Contro IL Cancro (ACC)
Postal address: VIA Giorgio Ribotta 5
Town: Roma
NUTS code: IT Italia
Postal code: 00144
Country: Italy
Contact person: Roberta Cardone
Internet address(es):
Main address:
Address of the buyer profile:
I.1)Name and addresses
Official name: Institut Curie
Postal address: rue d'Ulm 26
Town: Paris
NUTS code: FR France
Postal code: 75231
Country: France
Contact person: Maud Kamal
Internet address(es):
Main address:
Address of the buyer profile:
I.1)Name and addresses
Official name: Institut Catala d'Oncologia
Postal address: AV Gran via de l'Hospitalet 199-203
Town: L'Hospitalet de Llobregat
NUTS code: ES511 Barcelona
Postal code: 08908
Country: Spain
Contact person: Josep Maria Borras
Internet address(es):
Main address:
Address of the buyer profile:
I.1)Name and addresses
Official name: Institut Jules Bordet
Postal address: rue Heger Bordet 1
Town: Brussels
NUTS code: BE10 Région de Bruxelles-Capitale / Brussels Hoofdstedelijk Gewest
Postal code: 1000
Country: Belgium
Contact person: Phillipe Aftimos
Internet address(es):
Main address:
Address of the buyer profile:
I.1)Name and addresses
Official name: Ludwig-Maximilians-Universitaet Muenchen
Postal address: Geschwister Scholl Platz 1
Town: Munich
NUTS code: DE212 München, Kreisfreie Stadt
Postal code: 80539
Country: Germany
Contact person: Martin Dreyling
Internet address(es):
Main address:
Address of the buyer profile:
I.1)Name and addresses
Official name: Charite — Universitaetsmedizin Berlin
Postal address: Chariteplatz 1
Town: Berlin
NUTS code: DE300 Berlin
Postal code: 10117
Country: Germany
Contact person: Lars Bullinger
Internet address(es):
Main address:
Address of the buyer profile:
I.1)Name and addresses
Official name: Hospices Civils de Lyon
Postal address: quai des Celestins 3
Town: Lyon
NUTS code: FR France
Postal code: 69002
Country: France
Contact person: Pierre Sujobert
Internet address(es):
Main address:
Address of the buyer profile:
I.2)Information about joint procurement
The contract involves joint procurement
In the case of joint procurement involving different countries, state applicable national procurement law:

This pre-commercial procurement (PCP) is carried out by Scienciano who was appointed as lead procurer to coordinate and lead the joint procurement in the name and on behalf of the buyers group listed.

Access to the procurement documents is restricted. Further information can be obtained at:
Additional information can be obtained from the abovementioned address
I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity

Section II: Object

II.1)Scope of the procurement

Pre-commercial Procurement to Buy R&D (Research and Development) Services for the Development of an Affordable Integrated Solution for Predictive, Prognostic and Diagnostic Analysis in Liquid Biopsies

II.1.2)Main CPV code
73100000 Research and experimental development services
II.1.3)Type of contract
II.1.4)Short description:

This prior information notice (PIN) provides early information about the expected starting date and purchase volume for a pre-commercial procurement (PCP) and about the open market consultation that is organized in preparation of this procurement. More information about the open market consultation is provided in section II.2.14).

This procurement aims to trigger new solutions to be developed and tested to address the following challenge: successful implementation in routine clinical care practice of large ‘cellular free DNA’ molecular diagnostics based on NGS technology by means of a provision an integrated, cost-effectient and standardized sequencing and analytical data interpretation and reporting system in various oncology care settings in the EU.

II.1.5)Estimated total value
Value excluding VAT: 7 073 554.00 EUR
II.1.6)Information about lots
This contract is divided into lots: no
II.2.2)Additional CPV code(s)
33100000 Medical equipments
38000000 Laboratory, optical and precision equipments (excl. glasses)
48180000 Medical software package
71900000 Laboratory services
72100000 Hardware consultancy services
72200000 Software programming and consultancy services
72300000 Data services
72700000 Computer network services
73300000 Design and execution of research and development
73100000 Research and experimental development services
II.2.3)Place of performance
NUTS code: BE Belgique / België
NUTS code: ES España
NUTS code: DE Deutschland
NUTS code: FR France
NUTS code: IT Italia
Main site or place of performance:

Main site or place of performance: R&D will be performed mainly in Europe.

Testing is expected to take place in Brussels (BE); Paris, Lyon (FR); Berlin, Munich (GER);, Barcelona (SP), Milan, Rome (IT)

II.2.4)Description of the procurement:

The oncNGS buyers group aims to address their unmet needs:

(unmet need 1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all;

(unmet need 2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses;

(unmet need 3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests.

Through the provision of an (solution 1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (solution 2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (solution 3) an on-site ICT decision support system including analytical test interpretation and reporting.

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.

Each selected operator will be awarded a framework agreement that covers 3 R&D phases.

The 3 phases are:

— solution design,

— prototype development and analytical testing,

— pre-commercial devices clinical testing,

Phase 1: Solution design

Phase 1 suppliers will design their solution based on their background and their analysis of the technology strategy, technical feasibility, quality plan, risks assessment, business model, financial feasibility, ethics and data protection management done to satisfy oncNGS requirements. During Phase 1, suppliers will be requested to deliver the Analytical test plan they will perform in Phase 2.

This phase will require from the suppliers concise research and development to match any of their in-house tools to the needs of the buyers group. In silico/in vitro primer assessments, bioinformatics software adaptations, algorithm adaptation and form development will have to be taken up. At the end of the Phase 1, the invitation to Phase 2 (call-off) will be issued.

Phase 2: Prototype development and Analytical testing

Phase 2 suppliers will develop their solution and demonstrate their analytical validity having followed the Analytical test plan approved in Phase 1. The Analytical validation will consist of demonstration of assay performance (accuracy, precision, specificity, etc.). During Phase 2, suppliers will be requested to deliver the clinical validation protocol of the pre-commercial devices and Data Management Plan (‘DMP’) (including patients’ consents) they will perform in Phase 3.

This phase will require from the suppliers further research and development to optimize the in silico/in vitro defined primer combinations, the bioinformatics pipeline and interpretation and reporting algorithms when aiming to meet the criteria of analytic validation on sample DNA materials (sensitivity, specificity, transferability, robustness, etc). At the end of the Phase 2, the invitation to Phase 3 (call-off) will be issued.

Phase 3: Pre-commercial devices clinical testing

Phase 3 suppliers will validate their approved analytical solution on the oncNGS and demonstrate the clinical validity of the solution following the protocol approved in Phase 2 and authorized by the relevant ethical committees and all the other authorizing entities/agencies.

After each phase, intermediate evaluations will be carried out to progressively select the best of the competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase. Corroboration of the final solution is expected to take place in at the buyers’ facilities. This testing may also serve as a first customer test reference for the contractors.

II.2.14)Additional information

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions beyond this PCP.

II.3)Estimated date of publication of contract notice:

Section IV: Procedure

IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: no

Section VI: Complementary information

VI.3)Additional information:

All interested operators are invited to take part in an open market consultation (regardless of their geographic location, the size or governance structure of their organization).

The open market consultation will provide you with an overview on the procurement objectives, the PCP process and the main clauses of the contract. You will also have the opportunity to ask questions. It will be held in English.

The open market consultation will be organized though the combination of:

— on-line open events (including Q&A sessions) that will be held on:

• May 4 (morning),

• May 5 (afternoon).

The registration to the 2 events will be made available on 1 April 2021 at the project website

— a questionnaire made available at the project website on 6 May 2021, the day after the last on line open event, and to be replied by 20 May 2021. Participating economic operators willing to supply confidential information are required to indicate what specific information must be treated as confidential,

— on line meetings with each respondent to the questionnaire and that booked the meeting through the link provided in the questionnaire and on a first come first served basis. The meetings will take place during the weeks from 21 May 2021 to 28 May 2021 (excluding May 24th that is public holidays in several countries). These meetings will be held with the unique purpose to offer the economic operators to explain more in details their responses to the questionnaires.

Any economic operator can participate in the PCP call for tender even if it did not participate in the open market consultation.

Offers will be accepted only in English. All communication (before, during and after the procurement) will be carried out in English.

All information provided during the open market consultation and other background information will summarized be published online in English on the project website (

Participation in the open market consultation will not be a requirement to submit a proposal to the tender, does not lead to any rights or privileges for the participants, and is not part of any pre-qualification or selection process.

For more information, please see:

— the project website (

— the section on PCP on the EC website (

VI.5)Date of dispatch of this notice: